AMAG Pharmaceuticals (AMAG) Rating Reiterated by B. Riley

AMAG Pharmaceuticals (NASDAQ:AMAG)‘s stock had its “hold” rating reissued by stock analysts at B. Riley in a report issued on Tuesday. They presently have a $16.00 price target on the specialty pharmaceutical company’s stock. B. Riley’s target price would suggest a potential upside of 14.70% from the stock’s current price. B. Riley also issued estimates for AMAG Pharmaceuticals’ FY2022 earnings at $1.78 EPS.

Other equities research analysts also recently issued research reports about the company. Piper Jaffray Companies assumed coverage on AMAG Pharmaceuticals in a research report on Monday, October 23rd. They set a “neutral” rating and a $18.00 price target on the stock. Zacks Investment Research upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, November 8th. ValuEngine upgraded AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, January 3rd. Janney Montgomery Scott restated a “hold” rating on shares of AMAG Pharmaceuticals in a research report on Tuesday, October 17th. Finally, Morgan Stanley lowered their price target on AMAG Pharmaceuticals from $26.00 to $22.00 and set an “overweight” rating on the stock in a research report on Friday, November 3rd. Twelve research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average price target of $21.27.

AMAG Pharmaceuticals (NASDAQ AMAG) traded down $0.30 during trading hours on Tuesday, reaching $13.95. The company had a trading volume of 961,100 shares, compared to its average volume of 827,891. The company has a market capitalization of $474.63, a price-to-earnings ratio of -2.29 and a beta of 0.79. AMAG Pharmaceuticals has a 12 month low of $11.93 and a 12 month high of $25.20. The company has a quick ratio of 1.48, a current ratio of 1.59 and a debt-to-equity ratio of 0.94.

AMAG Pharmaceuticals (NASDAQ:AMAG) last posted its quarterly earnings data on Thursday, November 2nd. The specialty pharmaceutical company reported $1.57 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.04) by $1.61. AMAG Pharmaceuticals had a negative return on equity of 0.64% and a negative net margin of 35.35%. equities analysts predict that AMAG Pharmaceuticals will post -4.17 earnings per share for the current year.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Dupont Capital Management Corp increased its holdings in shares of AMAG Pharmaceuticals by 102.8% in the third quarter. Dupont Capital Management Corp now owns 19,731 shares of the specialty pharmaceutical company’s stock worth $364,000 after buying an additional 10,000 shares during the period. Prudential Financial Inc. increased its holdings in shares of AMAG Pharmaceuticals by 35.7% in the third quarter. Prudential Financial Inc. now owns 725,357 shares of the specialty pharmaceutical company’s stock worth $13,382,000 after buying an additional 190,660 shares during the period. Northern Trust Corp increased its holdings in shares of AMAG Pharmaceuticals by 6.1% in the second quarter. Northern Trust Corp now owns 464,647 shares of the specialty pharmaceutical company’s stock worth $8,550,000 after buying an additional 26,725 shares during the period. State Board of Administration of Florida Retirement System increased its holdings in shares of AMAG Pharmaceuticals by 94.4% in the third quarter. State Board of Administration of Florida Retirement System now owns 46,075 shares of the specialty pharmaceutical company’s stock worth $850,000 after buying an additional 22,374 shares during the period. Finally, Eii Capital Management Inc. increased its holdings in shares of AMAG Pharmaceuticals by 41.5% in the third quarter. Eii Capital Management Inc. now owns 119,690 shares of the specialty pharmaceutical company’s stock worth $2,208,000 after buying an additional 35,090 shares during the period.

WARNING: “AMAG Pharmaceuticals (AMAG) Rating Reiterated by B. Riley” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.dispatchtribunal.com/2018/01/18/amag-pharmaceuticals-amag-rating-reiterated-by-b-riley.html.

About AMAG Pharmaceuticals

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Analyst Recommendations for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply